Novartis AG
Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –
Novartis Jakavi (ruxolitinib by Year
Jakavi (ruxolitinib — myelofibrosis & polycythemia vera, ex-US commercial rights) ($M)
Novartis Jakavi (ruxolitinib: $2,110M in FY2025, up 9.0% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Jakavi | 2 110 | 1 936 | 9 | 7”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Jakavi (ruxolitinib — myelofibrosis & polycythemia vera, ex-US commercial rights) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,110 | +9.0% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 1,936 | +12.6% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 1,720 | +10.2% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 1,561 | -2.1% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 1,595 | +19.1% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 1,339 | +20.2% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 1,114 | +14.0% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 977 | +25.7% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2017 | Dec 31, 2017 | 777 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up jakavi (ruxolitinib
Cite this data
StockData. (2026). Novartis Jakavi (ruxolitinib ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-jakavi
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.